Angela M. Christiano

Angela M. Christiano

Auto-generated profile, based on publicly available information

Angela M. Christiano

Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LXLuzhou Xing
Luzhou Xing
ZDZhenpeng Dai
Zhenpeng Dai
AJAli Jabbari
Ali Jabbari
JCJane E Cerise
Jane E Cerise
CHClaire A Higgins
Claire A Higgins
RCRaphael Clynes
Raphael Clynes

1 July 2010 in Nature
Verified
Journal Article
Closed access
PDF file
LPLynn Petukhova
Lynn Petukhova
MDMadeleine Duvic
Madeleine Duvic
MHMaria Hordinsky
Maria Hordinsky
DNDavid Norris
David Norris
VPVera Price
Vera Price
ACAngela M. Christiano
Angela M. Christiano

21 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CHClaire A. Higgins
Claire A. Higgins
JCJames C. Chen
James C. Chen
JCJane E. Cerise
Jane E. Cerise
CJColin A. B. Jahoda
Colin A. B. Jahoda
ACAngela M. Christiano
Angela M. Christiano
Significance: Growth of de novo hair follicles in adult skin occurs by a process known as hair neogenesis. One way of initiating neogenesis is to place dermal papillae isolated from the hair follicle in contact with an overlying epidermis where they reprogram the epidermis to adopt a follicular fate. This approach, however, has not been successful using cultured human dermal papilla cells in human skin because the cells lose their ability to induce hair growth after expansion in vitro. In this paper, we demonstrate that by manipulating cell culture conditions to establish three-dimensional papilla spheroids, we restore dermal papilla inductivity. We also use several systems biology approaches to gain a comprehensive understanding of the molecular mechanisms that underlie this regenerative process.

13 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
HAHasan Erbil Abaci
Hasan Erbil Abaci
ACAbigail Coffman
Abigail Coffman
YDYanne Doucet
Yanne Doucet
JCJames Chen
James Chen
JJJoanna Jacków
Joanna Jacków
ACAngela M. Christiano
Angela M. Christiano
Human skin constructs (HSCs) have the potential to provide an effective therapy for patients with significant skin injuries and to enable human-relevant drug screening for skin diseases; however, the incorporation of engineered skin appendages, such as hair follicles (HFs), into HSCs remains a major challenge. Here, we demonstrate a biomimetic approach for generation of human HFs within HSCs by recapitulating the physiological 3D organization of cells in the HF microenvironment using 3D-printed molds. Overexpression of Lef-1 in dermal papilla cells (DPC) restores the intact DPC transcriptional signature and significantly enhances the efficiency of HF differentiation in HSCs. Furthermore, vascularization of hair-bearing HSCs prior to engraftment allows for efficient human hair growth in immunodeficient mice. The ability to regenerate an entire HF from cultured human cells will have a transformative impact on the medical management of different types of alopecia, as well as chronic wounds, which represent major unmet medical needs.

22 January 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRegina C. Betz
Regina C. Betz
LPLynn Petukhova
Lynn Petukhova
SRStephan Ripke
Stephan Ripke
HHHailiang Huang
Hailiang Huang
AMAndroniki Menelaou
Androniki Menelaou
ACAngela M. Christiano
Angela M. Christiano
Alopecia areata (AA) is a prevalent autoimmune disease with 10 known susceptibility loci. Here we perform the first meta-analysis of research on AA by combining data from two genome-wide association studies (GWAS), and replication with supplemented ImmunoChip data for a total of 3,253 cases and 7,543 controls. The strongest region of association is the major histocompatibility complex, where we fine-map four independent effects, all implicating human leukocyte antigen-DR as a key aetiologic driver. Outside the major histocompatibility complex, we identify two novel loci that exceed the threshold of statistical significance, containing ACOXL/BCL2L11(BIM) (2q13); GARP (LRRC32) (11q13.5), as well as a third nominally significant region SH2B3(LNK)/ATXN2 (12q24.12). Candidate susceptibility gene expression analysis in these regions demonstrates expression in relevant immune cells and the hair follicle. We integrate our results with data from seven other autoimmune diseases and provide insight into the alignment of AA within these disorders. Our findings uncover new molecular pathways disrupted in AA, including autophagy/apoptosis, transforming growth factor beta/Tregs and JAK kinase signalling, and support the causal role of aberrant immune processes in AA.

22 September 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
MCMilène Kennedy Crispin
Milène Kennedy Crispin
JKJustin M. Ko
Justin M. Ko
BCBrittany G. Craiglow
Brittany G. Craiglow
SLShufeng Li
Shufeng Li
GSGautam Shankar
Gautam Shankar
BKBrett A. King
Brett A. King
BACKGROUND. Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8 + T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined. METHODS. This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU). Tofacitinib (5 mg) was given twice daily for 3 months. Endpoints included regrowth of scalp hair, as assessed by the severity of alopecia tool (SALT), duration of hair growth after completion of therapy, and disease transcriptome. RESULTS. Of 66 subjects treated, 32% experienced 50% or greater improvement in SALT score. AA and ophiasis subtypes were more responsive than AT and AU subtypes. Shorter duration of disease and histological peribulbar inflammation on pretreatment scalp biopsies were associated with improvement in SALT score. Drug cessation resulted in disease relapse in 8.5 weeks. Adverse events were limited to grade I and II infections. An AA responsiveness to JAK/STAT inhibitors score was developed to segregate responders and nonresponders, and the previously developed AA disease activity index score tracked response to treatment. CONCLUSIONS. At the dose and duration studied, tofacitinib is a safe and effective treatment for severe AA, though it does not result in a durable response. Transcriptome changes reveal unexpected molecular complexity within the disease. TRIAL REGISTRATION. ClinicalTrials.gov NCT02197455 and NCT02312882. FUNDING. This work was supported by the US Department of Veterans Affairs Office of Research and Development, National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health grant R01 AR47223 and U01 AR67173, the National Psoriasis Foundation, the Swedish Society of Medicine, the Fernström Foundation, the Locks of Love Foundation, the National Alopecia Areata Foundation, and the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.